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and Andrea B. Troxel1
Psoriasis is a common, chronic, inflammatory disease. Psoriasis has been hypothesized to be associated with an
increased risk of lymphoma due to its pathophysiology, its treatments, or a combination of these factors. We
performed a large population-based cohort study of the risk of lymphoma in psoriasis patients using the
General Practice Research Database. We identified 153,197 patients with psoriasis and 765,950 corresponding
subjects without psoriasis. Psoriasis patients who received a systemic treatment consistent with extensive
disease were classified as severe (N¼ 3,994) and those who did not receive systemic therapies were classified as
mild (N¼ 149,203). The analyses were adjusted for age, gender, and person–time using a Cox proportional
hazards model. For mild and severe psoriasis patients, the respective adjusted relative risks for lymphoma and
its subtypes were as follows: all lymphoma 1.34 (1.16, 1.54) and 1.59 (0.88, 2.89); non-Hodgkin’s lymphoma 1.15
(0.97, 1.37) and 0.73 (0.28, 1.96); Hodgkin’s lymphoma (HL) 1.42 (1.00, 2.02) and 3.18 (1.01, 9.97); cutaneous T-cell
lymphoma (TCL) 4.10 (2.70, 6.23) and 10.75 (3.89, 29.76). Psoriasis is associated with an increased risk of
lymphoma. The association is strongest for HL and CTCL. The excess risk of lymphoma attributed to psoriasis
was 7.9/100,000 psoriasis patients per year. Although patients with psoriasis have an increased relative risk of
lymphoma, the absolute risk attributable to psoriasis is low given that lymphoma is a rare disease and the
magnitude of association is modest.
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INTRODUCTION
Psoriasis is a common, chronic disease that affects approxi-
mately 2–3% of the adult population (Gelfand et al., 2005c).
The extent of body surface area (BSA) affected by psoriasis is
variable, ranging from limited (i.e., o2% body surface area)
disease in approximately 80–85% of patients, to more
extensive skin involvement in approximately 15–20% of
patients (Gelfand et al., 2004, 2005b; Stern et al., 2004).
Psoriasis has serious impacts on health-related quality of life,
even in patients with limited body surface area involvement
(Rapp et al., 1999; Gelfand et al., 2004). The pathophysio-
logy of psoriasis involves an abnormal immune response
characterized by increased activity of T cells, antigen-
presenting (e.g., dendritic) cells, and Th-1 cytokines (Krueger
and Bowcock, 2005). Other investigators have also demons-
trated increased B lymphocyte activity in patients with
psoriasis, which suggests broad immune activation (Muller
et al., 1991; Jeffes et al., 1995; Mahmoud et al., 1999).
The immunologic nature of psoriasis has raised concern
that its pathophysiology may be associated with an increased
risk of lymphoma, as has been demonstrated previously for
other Th-1 mediated diseases such as rheumatoid arthritis
(Gridley et al., 1993; Ekstrom et al., 2003). Additionally,
patients with extensive psoriasis may be treated with systemic
therapies such as cyclosporine and methotrexate, which have
been associated with the development of lymphoma in
psoriasis patients treated with these medications (Koo et al.,
1992; Kamel et al., 1996, 1997; Cliff et al., 1999; Mahe et al.,
2003; Lelievre et al., 2005). Patients with psoriasis are
increasingly treated with biologic therapies that target T cells
(e.g., efazilumab, alefacept) or cytokines such as tumor
necrosis factor-a (infliximab, etanercept, adalimumab). There
is theoretical concern that biologic therapies may also
increase the risk of lymphoma given their mechanism of
action. Large, long-term observational studies of biologics
therapies in psoriasis patients are not yet published.
Epidemiologic studies in rheumatoid arthritis patients have
found increased rates of lymphoma in patients treated with
tumor necrosis factor inhibitors (Wolfe and Michaud, 2004;
Geborek et al., 2005); however, it is unclear if this risk is due
to the severity of rheumatoid arthritis or the tumor necrosis
factor inhibition treatment (e.g., confounding by indication).
Lymphomas are divided into two broad categories, non-
Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL).
The majority of lymphomas (88%) are NHL with the
remaining 12% being HL (Fisher and Fisher, 2004). Studying
the risk of lymphoma in psoriasis patients is challenging
because lymphoma is statistically rare, and therefore large
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sample sizes need to be studied to yield robust findings.
Although lymphoma is rare, it is of clinical and public health
importance given that NHL is the fifth most common cause of
cancer in the US, affecting 19/100,000 individuals per year
(an incidence similar to melanoma) (Bierman et al., 2004).
The incidence of NHL has increased approximately 3–4% per
year since 1973 and the current overall five year survival is
only 53%. Approximately 85% of NHL is B cell in origin
(Bierman et al., 2004). Cutaneous T-cell lymphoma (CTCL) is
the most common form of T-cell lymphoma, affecting approxi-
mately 0.5–1.0/100,000 individuals per year (Willemze et al.,
1997; Weinstock and Gardstein, 1999; Kim et al., 2005).
CTCL is of special interest given that it is a T-cell lymphoma
of the skin, and therefore may be related to the pathophysio-
logy of psoriasis.
There have been multiple previous studies of the risk of
lymphoma in psoriasis patients from both the United States
and Europe (Lindelof et al., 1990; Doody et al., 1992; Bhate
et al., 1993; Hannuksela et al., 1996; Stern and Vakeva, 1997;
Frentz and Olsen, 1999; Hannuksela-Svahn et al., 1999, 2000;
Tavani et al., 2000; Boffetta et al., 2001; Margolis et al., 2001;
Gelfand et al., 2003; Morales et al., 2003; Zhang et al., 2004;
Becker et al., 2005). These studies have varied in their design,
sample size, population, and outcome (e.g., all lymphoma,
NHL, HL, and CTCL) studied. Many of these studies did not
report the relative risk of various forms of lymphoma, tended
to concentrate on highly selected populations of patients with
psoriasis such as those hospitalized for their disease or those
treated with psoralen, and were not population-based. The
results of these studies have been conflicting, and therefore
additional studies are necessary to clarify this association,
especially since patients with psoriasis are increasingly being
treated on a long-term basis with systemic therapies that
selectively target the immune system (i.e., biologics). The
purpose of this investigation was to perform a broadly
representative, population-based cohort study of the risk of
all lymphoma, NHL, HL, and CTCL in patients with psoriasis.
RESULTS
We identified 153,197 patients with psoriasis and 765,950
corresponding subjects without psoriasis (Table 1). Psoriasis
patients were older than control patients, and mild psoriasis
patients were slightly more likely to be females. In unadjusted
analyses, both mild and severe psoriasis patients were more
likely to have a history of lymphoma at the time the study was
initiated. Among psoriasis patients, 2.6% were classified as
Table 1. Description of study groups
Variable Control Mild psoriasis Severe psoriasis
N (%) 765,950 149,203 3,994
Gender
Male 366,238 (48%) 70,742 (47.4%) 1,937 (48.5%)
Female 399,712 (52%) 78,461 (52.6%) 2,057 (51.5%)
Odds ratio (95% CI) — 0.98 (0.97, 1.00) 1.03 (0.97, 1.09)
P=0.0045 P=0.3912
Age
Mean (median, 25th, 75th percentile) 35.76 (33, 18, 53) 41.51 (40, 26, 57) 48.51 (48, 35, 62)
Po0.001 Po0.001
History of lymphoma
Yes 538 (0.07%) 179 (0.12%) 11 (0.28%)
No 765,412 (99.93%) 149,024 (99.88%) 3,983 (99.72%)
Odds ratio (95% CI) — 1.71 (1.44, 2.03) 3.93 (1.95, 7.09)
Po0.0001 P=0.0002
Systemic therapies (N (%))
Methotrexate — — 2,314 (57.94%)
Psoralen/phototherapy — — 681 (17.05%)
Azathioprine — — 659 (16.50%)
Ciclosporine — — 414 (10.37%)
Etretinate or acitretin — — 351 (8.79%)
Hydroxyurea — — 224 (5.61%)
Mycophenolate mofetil — — 12 (0.30%)
CI, confidence interval.
Odds ratios and P-values refer to the comparison of the mild and severe psoriasis groups with the control group. Percentages for systemic therapies do not
add to 100 because patients could have received more than one systemic therapy.
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severe based on having received a systemic treatment for
psoriasis. The frequency of use of oral therapies for psoriasis
was similar to that reported in other population-based studies
from the UK (Nevitt and Hutchinson, 1996). The majority of
patients classified with severe psoriasis received methotrexate
(58%). Documentation of psoralen and phototherapy use was
low (17% of patients with severe disease) and may under-
represent the true use of these agents, as they are restricted to
dermatologists and their use may not be well captured
electronically by the general practitioner.
Psoriasis patients had an increased hazard ratio (HR) (i.e.,
risk) of lymphoma (Table 2) that persisted when adjusting for
age and gender (HR 1.35, 95% CI 1.17, 1.55). The adjusted
risk of lymphoma was elevated in mild (HR 1.34, 95% CI
1.16, 1.54) and severe psoriasis (HR 1.59, 95% CI 0.88, 2.89)
patients; however, the association did not achieve conven-
tional levels of statistical significance in the severe group.
The risk of all lymphoma was slightly greater in our
sensitivity analysis, which was restricted to subjects with at
least 6 months of follow-up time and who did not have a
history of lymphoma or a lymphoma in the first 6 months of
observation.
The primary analysis for NHL (Table 3, excluding CTCL)
found a small increased risk that was not statistically
significant for all psoriasis patients (HR 1.14, 95% CI 0.96,
1.35) and for mild patients (HR 1.15, 95% CI 0.97, 1.37).
There was no increased risk in the severe group (HR 0.73,
95% CI 0.28, 1.96). Sensitivity analyses slightly increased the
degree of association leading to statistical significance in all
psoriasis patients (HR 1.26, 95% CI 1.04, 1.52) and mild
psoriasis patients (HR 1.27, 95% CI 1.05, 1.54), but not in
severe psoriasis patients (HR 0.96, 0.36, 2.57).
The adjusted risk of HL (Table 4) was increased in all
psoriasis patients (HR 1.48, 1.05, 2.08). The risk of HL was
also increased in both the mild (HR 1.42, CI 1.00 2.02) and
severe psoriasis (HR 3.18, 95% CI 1.01, 9.97) groups. In
sensitivity analyses, the risk of Hodgkin’s remained elevated
but with borderline statistical significance in all psoriasis
patients (HR 1.54, 95% CI 0.99, 2.40) and in patients with
mild psoriasis (HR 1.53, 95% CI 0.98, 2.40); however, it was
no longer statistically significant in the severe group (HR
1.79, 95% CI 0.25, 12.90).
The strongest association of lymphoma with psoriasis
occurred for CTCL (Table 5). The adjusted risk of CTCL in all
psoriasis patients was 4.34 (95% CI 2.89, 6.52). The adjusted risk
of CTCL was substantially increased in both mild psoriasis
(HR 4.10, 95% CI 2.70, 6.23) and severe psoriasis (HR 10.75,
95% CI 3.89, 29.76). Sensitivity analyses found a greater magni-
tude of association between CTCL and the psoriasis groups.
In all of the models described above, Poisson models
resulted in very similar estimates for all of the observed
effects. Additionally, tests for effect modification with respect
to age and gender for all models in all psoriasis patients were
nonsignificant.
Table 2. Incidence and relative risk (hazard) of lymphoma in psoriasis patients compared to controls
Variable Control Mild psoriasis Severe psoriasis All psoriasis
Mean follow-up time
(median, 25th, 75th percentile)
5.61 (5.25, 2.18, 9.13) 4.50 (3.80, 1.64, 7.09) 5.77 (5.53, 2.70, 8.96) 4.54 (3.84, 1.67, 7.16)
Person years (N) 4,297,296 671,914 23,048 694,962
New lymphoma (N) 970 237 11 248
Incidence per 10,000 person years (95% CI) 2.26 (2.12, 2.40) 3.53 (3.09, 4.01) 4.77 (2.38, 8.54) 3.57 (3.14, 4.04)
Primary analysis
Unadjusted hazard ratio — 1.54 (1.33, 1.77) 2.12 (1.17, 3.85) 1.56 (1.35, 1.79)
Po0.001 P=0.013 Po0.001
Adjusted hazard ratio1 — 1.34 (1.16, 1.54) 1.59 (0.88, 2.89) 1.35 (1.17, 1.55)
Po0.001 P=0.124 Po0.001
Attributable risk (excess number of
lymphoma cases related to psoriasis)
— — — 7.9/100,000 per year
Sensitivity analysis2
New lymphoma (N) 711 183 9 192
Unadjusted hazard ratio — 1.71 (1.45, 2.01) 2.37 (1.23, 4.57) 1.73 (1.48, 2.03)
Po0.001 P=0.010 Po0.001
Adjusted hazard ratio1 — 1.48 (1.25, 1.74) 1.78 (0.92, 3.44) 1.49 (1.27, 1.75)
Po0.001 P=0.085 Po0.001
CI, confidence interval.
1Adjusted for gender, age.
2Restricted to subjects with at least 6 months of follow-up time who did not have a history of lymphoma or a lymphoma in the first six months.
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Table 3. Incidence and relative risk (hazard) of NHL in psoriasis patients compared to controls
Variable Control Mild psoriasis Severe psoriasis All psoriasis
Mean follow-up time
(median, 25th, 75th percentile)
5.61 (5.25, 2.18, 9.13) 4.51 (3.81, 1.65, 7.09) 5.77 (5.53, 2.70, 8.96) 4.54 (3.84, 1.67, 7.16)
Person years (N) 4,298,107 672,168 23,061 695,230
New NHL (N) 759 159 4 163
Incidence per 10,000 person years (95% CI) 1.77 (1.64, 1.90) 2.37 (2.01, 2.76) 1.73 (0.47, 4.44) 2.35 (2.00, 2.73)
Primary analysis
Unadjusted hazard ratio — 1.33 (1.12, 1.58) 0.99 (0.37, 2.63) 1.32 (1.11, 1.56)
P=0.001 P=0.980 P=0.001
Adjusted hazard ratio1 — 1.15 (0.97, 1.37) 0.73 (0.28, 1.96) 1.14 (0.96, 1.35)
P=0.103 P=0.539 P=0.134
Sensitivity analysis2
New NHL (N) 581 128 4 132
Unadjusted hazard ratio — 1.47 (1.21, 1.78) 1.29 (0.48, 3.45) 1.47 (1.21, 1.77)
Po0.001 P=0.612 Po0.001
Adjusted hazard ratio1 — 1.27 (1.05, 1.54) 0.96 (0.36, 2.57) 1.26 (1.04, 1.52)
P=0.015 P=0.939 P=0.018
CI, confidence interval; NHL, non-Hodgkin’s lymphoma.
1Adjusted for gender, age.
2Restricted to subjects with at least 6 months of follow-up time who did not have a history of lymphoma or a lymphoma in the first six months.
Table 4. Incidence and relative risk (hazard) of HL in psoriasis patients compared to controls
Variable Control Mild psoriasis Severe psoriasis All psoriasis
Mean follow-up time
(median, 25th, 75th percentile)
5.61 (5.25, 2.19, 9.13) 4.51 (3.81, 1.65, 7.10) 5.77 (5.52, 2.70, 8.96) 4.54 (3.85, 1.67, 7.16)
Person years (N) 4,299,128 672,418 23,063 695,482
New Hodgkin’s lymphoma (N) 160 39 3 42
Incidence per 10,000 person years (95% CI) 0.37 (0.32, 0.44) 0.58 (0.41, 0.79) 1.30 (0.27, 3.80) 0.60 (0.44, 0.82)
Primary analysis
Unadjusted hazard ratio — 1.48 (1.04, 2.10) 3.50 (1.12 10.96) 1.54 (1.10, 2.17)
P=0.029 P=0.032 P=0.012
Adjusted hazard ratio1 — 1.42 (1.00, 2.02) 3.18 (1.01, 9.97) 1.48 (1.05, 2.08)
P=0.052 P=0.048 P=0.025
Attributable risk (excess number of
lymphoma cases related to psoriasis)
1.8/100,000 per year
Sensitivity analysis2
New HL (N) 98 24 1 25
Unadjusted hazard ratio — 1.58 (1.01, 2.47) 1.91 (0.27, 13.68) 1.59 (1.03, 2.47)
P=0.045 P=0.521 P=0.038
Adjusted hazard ratio1 — 1.53 (0.98, 2.40) 1.79 (0.25, 12.90) 1.54 (0.99, 2.40)
P=0.063 P=0.561 P=0.055
HL, Hodgkin’s lymphoma; CTCL, cutaneous T-cell lymphoma.
1Adjusted for gender, age.
2Restricted to subjects with at least 6 months of follow-up time who did not have a history of lymphoma or a lymphoma in the first 6 months.
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DISCUSSION
To our knowledge, this is the largest study to date to
determine the risk of lymphoma in patients with psoriasis.
Particular strengths of this study, in addition to its size,
include its broadly representative nature and its population-
based design, which helps minimize selection and informa-
tion bias. We have also conducted detailed analyses of
subtypes of lymphoma, and conducted sensitivity analyses to
determine if the results were robust to different analytical
approaches.
The risk of all lymphoma was increased in all psoriasis
patients and mild psoriasis patients. The risk of all lymphoma
was increased slightly in patients with severe psoriasis, but
the finding was not statistically significant. The magnitude of
association of all lymphoma in the current study is lower than
in our previous study, in which we examined only patients
who were 65 years of age or older in the General Practice
Research Database (GPRD) from 1988 to 1996 (HR 2.94,
95% CI 1.82, 4.74) (Gelfand et al., 2003). The relative risk of
lymphoma in psoriasis patients was similar across age groups
in the current study, suggesting that the discrepancy may be
due to statistical variability (the current study had approxi-
mately 70 times more person time in the psoriasis group than
our previous study). Interestingly, a case–control study
suggested that older psoriasis patients may have a higher
relative risk of lymphoma than younger psoriasis patients
(Tavani et al., 2000); however, the relationships among age,
psoriasis, and the risk of lymphoma are difficult to interpret
due to sample size limitations. Additionally, the current study
occurred over a longer time period, suggesting the possibility
that lymphoma rates in older psoriasis patients may be
changing over time.
The overall risk for lymphoproliferative malignancies
was also increased in a study using an administrative
Medicaid database, which found an increased risk for
patients with psoriasis who received systemic therapies (RR
7.95, 95% CI 4.94, 12.79) and for those who did not receive
systemic therapies (RR 2.11, 95% CI 1.63, 2.74) (Margolis
et al., 2001). This study did not address subtypes of
lymphoma and therefore it is unclear which form(s) of
lymphoma accounted for the high relative risk in the severe
group. In particular, CTCL is strongly associated with severe
psoriasis (discussed below) and therefore may have ac-
counted for much of this increased risk. Additionally, this
study used an administrative database that covers an indigent
patient population, which may have led to greater misclassi-
fication between psoriasis and CTCL, and concerns regarding
the generalizability of the results. Other studies have not
observed an increased risk for all lymphoma in psoriasis
patients identified through general practitioners (Bhate et al.,
1993) or in those treated with psoralen (Stern and Vakeva,
1997).
Table 5. Incidence and relative risk (hazard) of cutaneous T-cell lymphoma in psoriasis patients compared
to controls
Variable Control Mild psoriasis Severe psoriasis All psoriasis
Mean follow-up time
(median, 25th, 75th percentile)
5.61 (5.25, 2.19, 9.13) 4.51 (3.81, 1.65, 7.10) 5.77 (5.53, 2.70, 8.96) 4.54 (3.85, 1.67, 7.16)
Person years (N) 4,299,563 672,383 23,054 695,437
New CTCL (N) 51 39 4 43
Incidence per 10,000 person years (95% CI) 0.12 (0.09, 0.16) 0.58 (0.41, 0.79) 1.74 (0.47, 4.44) 0.62 (0.45, 0.83)
Primary analysis
Unadjusted hazard ratio — 4.78 (3.15, 7.27) 14.60 (5.28, 40.40) 5.08 (3.38, 7.64)
Po0.001 Po0.001 Po0.001
Adjusted hazard ratio1 — 4.10 (2.70, 6.23) 10.75 (3.89, 29.76) 4.34 (2.89, 6.52)
Po0.001 Po0.001 Po0.001
Attributable risk (excess number of
lymphoma cases related to psoriasis)
4.0/100,000 per year
Sensitivity analysis2
New CTCL (N) 32 31 4 35
Unadjusted hazard ratio — 6.37 (3.88, 10.46) 23.21 (8.21, 65.62) 6.89 (4.26, 11.15)
Po0.001 Po0.001 Po0.001
Adjusted hazard ratio1 — 5.42 (3.30, 8.89) 17.18 (6.07, 48.58) 5.84 (3.61, 9.44)
Po0.001 Po0.001 Po0.001
CI, confidence interval; CTCL, cutaneous T-cell lymphoma.
1Adjusted for gender, age.
2Restricted to subjects with at least 6 months of follow-up time who did not have a history of lymphoma or a lymphoma in the first 6 months.
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The strongest association of lymphoma and psoriasis
occurred for CTCL. This finding is similar to the few previous
studies that have specifically examined the risk of T-cell
lymphoma and CTCL in psoriasis (Boffetta et al., 2001;
Morales et al., 2003; Zhang et al., 2004). Interestingly, those
we classified as having severe psoriasis had the most strongly
elevated relative risk of CTCL. Previous studies of patients
with severe psoriasis have also found strongly increased
relative risks of CTCL. For example, studies of patients
hospitalized for psoriasis have found standardized incidence
ratios of 19.3 (95% CI 6.22, 45) (Boffetta et al., 2001) and
15.1 (95% CI 4.1, 38) (Frentz and Olsen, 1999) for the risk of
developing CTCL. A population based study of lymphoma in
the US, in which patients identified as having psoriasis are
broadly representative and likely be similar to those in our
current study, found an odds ratio of 3.7 (95% CI 1.3, 10.6)
for T-cell lymphoma, which is similar in magnitude to our
findings in all psoriasis patients (Zhang et al., 2004).
The strong association between psoriasis and CTCL may
be related to chronic lymphoproliferation in psoriasis which
eventually leads to a dominant clone and evolution to CTCL
in some patients. Alternatively, certain psoriasis therapies,
misdiagnosis, or a combination of these factors may explain
the association. The relative contribution of the pathophysio-
logy of psoriasis, psoriasis treatment, and/or misdiagnosis to
the increased risk of CTCL in psoriasis patients requires
further study. We believe that is it unlikely that misdiagnosis
completely explains this association as patients we classified
as having severe psoriasis would have been seen by der-
matologists based on the UK system of care (e.g., for initiation
of treatment of their severe psoriasis). Additionally, it has
been our clinical experience that some patients with well
documented psoriasis have evolved into CTCL, and we
have had patients who exhibit clinical and histological
features of both psoriasis and CTCL. The risk of CTCL in
patients with psoriasis is especially important because these
patients are increasingly treated with immunologic therapies,
which have the capacity to exacerbate lymphoma. For
example, case reports have suggested that tumor necrosis
factor inhibition may be associated with rapid progression of
CTCL, resulting in extensive disease and death (Adams et al.,
2004).
The risk of HL was also increased in psoriasis patients. The
magnitude of association between psoriasis and Hodgkin’s
was similar in patients with mild and severe psoriasis. In
addition, our results were similar to those reported in patients
hospitalized for psoriasis (standardized incidence ratio 3.3,
95% CI 1.4, 6.4) (Hannuksela-Svahn et al., 2000). These
results suggest that psoriasis patients have an increased risk of
HL and that the degree of risk may be independent of
psoriasis severity or systemic treatment for psoriasis. Other
studies have not found an association between psoriasis and
HL (Lindelof et al., 1990; Tavani et al., 2000; Boffetta et al.,
2001); however, these studies were limited by statistical
power, as Hodgkin’s is a very rare form of lymphoma.
NHL was found to only be slightly increased in the mild
psoriasis group, and this finding did not reach conventional
levels of statistical significance in our primary analysis. There
was no evidence of an increased risk of NHL in patients with
severe psoriasis. This finding is in contrast to studies in
patients hospitalized for psoriasis (standardized incidence
ratio 2.2, 95% CI 1.4, 3.4) (Hannuksela-Svahn et al., 2000) or
treated with psoralen plus UV light A (standardized incidence
ratio 3.7, CI 1.2, 8.6) (Hannuksela-Svahn et al., 1999), which
demonstrated an increase in NHL. It is unclear if these studies
excluded CTCL in their analysis of NHL, which may have led
to an overestimation of the risk of NHL, given the strong
association between psoriasis and CTCL demonstrated by the
current study. Other large studies that investigated patients
hospitalized for psoriasis (Frentz and Olsen, 1999; Boffetta
et al., 2001) or those deemed to have moderate to severe
psoriasis (Lindelof et al., 1990) did not find an increased risk
of NHL. Finally, an additional population-based study did not
find an increased risk of-B cell lymphoma, the most common
form of NHL, in patients with psoriasis (Zhang et al., 2004).
As with all studies, there are limitations to consider. First,
we were unable to account for the extent of skin involvement
of psoriasis in classifying the severity of psoriasis. Since the
majority of the general population of psoriasis patients have
limited disease, our analyses in the mild group are weighted
towards patients with limited psoriasis (Nevitt and Hutchinson,
1996; Stern et al., 2004; Gelfand et al., 2005b, c). Additionally,
since systemic therapies are used uncommonly in psoriasis
patients, our severe group was relatively small, which reduced
our statistical power when estimating the risk of lymphoma in
this group. We also did not control for sun exposure, which
has been implicated as a risk factor for lymphoma in some
studies, but data on this potential association remain incon-
clusive with recent studies finding a protective effect (Fisher
and Fisher, 2004; Smedby et al., 2005).
In conclusion, we have demonstrated that psoriasis is
associated with an increased risk of lymphoma. However, it
is important to consider the subtype of lymphoma when
investigating this association. The association between NHL
(excluding CTCL) and psoriasis was small in this study and
based on previously published data, this association is
inconsistent. The emerging evidence suggests an association
between HL and psoriasis; however, additional studies are
necessary to confirm this finding. The relative risk of
lymphoma in patients with psoriasis is greatest for CTCL,
which may be strongly elevated in patients with severe
disease. Although patients with psoriasis may have an
increased relative risk of lymphoma, the absolute risk
attributable to psoriasis is low given that lymphoma is a rare
disease and the magnitude of association is modest.
MATERIALS AND METHODS
Study design
This was a retrospective cohort study with data collected prospec-
tively from 1988 to 2002 by more than 500 general practitioners in
the UK, who were unaware of the hypothesis to be tested. The data
were collected as part of the patient’s electronic medical record and
are maintained in the GPRD. GPRD contains data on over 8 million
persons with over 35 million person-years of follow-up time and is
broadly representative of the UK population (Gelfand et al., 2005a).
General Practitioners receive specific training, financial induce-
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ments, and penalties to ensure accuracy of the data. GPRD has been
used extensively for epidemiologic studies. The validity of using the
GPRD to study psoriasis and lymphoma has been demonstrated
previously (Jick et al., 1991; Walley and Mantgani, 1997; Lewis
et al., 2001; Gelfand et al., 2003, 2005b, c). Additionally, the
epidemiology of lymphoma in the GPRD is similar to population-
based estimates in the US and UK (Parkin et al., 1999; SEER, 2001).
The study population consisted of all psoriasis patients (i.e.,
exposed population, see study groups below) who had at least 1 day
of observation time. Each psoriasis patient was matched to up to five
control subjects (as available based on matching criteria) who did
not have psoriasis (i.e., not exposed to psoriasis), who were seen in
the same practice, and who had a date of observation in the practice
(the maximum of the date when the patient registered with the
practice and the date when the practice was designated ‘‘up to
standard’’ (UTS)) within 60 days. Therefore, we assured that those
with and without psoriasis were followed by the same practices
during similar time periods. For control patients, observation start
time was the maximum of the patient registration and UTS dates. For
patients with psoriasis, observation start time was the maximum of
the patient registration, UTS, and psoriasis diagnosis dates. For all
patients, follow-up time ended when they developed a lymphoma,
died, transferred out of the practice, or the practice was no longer
UTS (whichever came earliest). Practices are designated UTS when
audits demonstrate that at least 95% of relevant patient encounters
are recorded and the data are determined to be of suitable quality for
epidemiologic research.
Study groups
Diseases are classified in the GPRD using Oxford Medical
Information System and Read codes. Oxford Medical Information
System and Read codes are diagnostic codes that GPs use as part of
the patient’s electronic medical record. Patients were classified as
having psoriasis if they ever received a diagnostic code for psoriasis,
which has been previously validated as described above. Psoriasis
patients were defined as having ‘‘severe’’ disease if they received a
treatment code consistent with severe disease (e.g., psoralen,
phototherapy, methotrexate, azathioprine, cyclosporine, etretinate,
acitretin, hydroxyurea, and mycophenolate) prior to the first
diagnostic code of lymphoma during the study period. Treatments
consistent with severe psoriasis were determined by the British
National Formulary and the opinion of two dermatologists (D.J.M.,
J.M.G.). Psoriasis was classified as ‘‘mild’’ if the patients never
received a prescription code consistent with severe disease during
the study period. Patients were classified as controls if they never
received a diagnostic code consistent with psoriasis.
Outcomes
Patients were classified as having a new lymphoma if they received a
medical code consistent with this diagnosis after the start date and
on or before the end date. Lymphoma was classified as NHL, HL,
and CTCL based on diagnostic codes. For patients who received
more then one code for lymphoma after the start date, the most
specific code was used to classify the lymphoma.
Statistical analysis
The data were summarized descriptively. Associations between the
presence of psoriasis and age, gender, and history of lymphoma were
tested using Fisher’s exact test for categorical variables and t-test for
continuous variables.
The rates of lymphoma in the psoriasis groups were compared to
the rate of lymphoma in the control population using an unadjusted
Cox proportional hazards model. The rates were then adjusted for
age and sex. We also tested for effect modification by age or gender
in all psoriasis patients on the relative risk of the various outcomes
studied by incorporating interaction terms. Each dichotomous
variable in the model was checked for proportionality while
adjusting for the other covariates in the model by examining
diagnostic log–log survival plots, which demonstrated adequate
proportionality. We also performed Poisson regression to assess
whether the modeling approach affected the results. In order to
maximize the number of lymphoma outcomes available, we did not
exclude patients with a history of lymphoma from the primary
analysis based on the assumption that the onset of psoriasis likely
predated the onset of lymphoma for most cases based on the
epidemiology of the two diseases. To test this assumption, we
performed a sensitivity analysis in which patients had to have at least
6 months of follow-up time and could not have had a history of
lymphoma or a lymphoma in the first 6 months in order to ensure the
capture of incident, not prevalent, lymphoma.
All statistical analyses were performed using Intercooled Stata 8.2
(Stata Corp, College Station, TX).
Protection of study subjects
Data utilized for this study were stripped of personally identifiable
information. The study was approved by the Office of Regulatory
Affairs of the University of Pennsylvania and by the Scientific and
Ethical Advisory Group of the Medicines Control Agency, UK. The
study was conducted in concordance with the Declaration of
Helsinki Principles.
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